A month has gone by since the last earnings report for Exact Sciences (EXAS). Shares have lost about 10.6% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Exact Sciences due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended upward during the past month.
The consensus estimate has shifted -20.69% due to these changes.
VGM Scores
At this time, Exact Sciences has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Exact Sciences has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Exact Sciences is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Exelixis (EXEL), a stock from the same industry, has gained 6%. The company reported its results for the quarter ended December 2024 more than a month ago.
Exelixis reported revenues of $566.76 million in the last reported quarter, representing a year-over-year change of +18.2%. EPS of $0.55 for the same period compares with $0.33 a year ago.
Exelixis is expected to post earnings of $0.42 per share for the current quarter, representing a year-over-year change of +147.1%. Over the last 30 days, the Zacks Consensus Estimate has changed -1.8%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Exelixis. Also, the stock has a VGM Score of A.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Exact Sciences Corporation (EXAS) : Free Stock Analysis Report
Exelixis, Inc. (EXEL) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Comments